U.S. Markets close in 57 mins.

Onconova Therapeutics, Inc. (ONTX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.035+0.045 (+2.236%)
As of 2:44PM EDT. Market open.
People also watch
OMEDOGXICNATHTBXVSTM

Onconova Therapeutics, Inc.

375 Pheasant Run
Newtown, PA 18940
United States
267-759-3680
http://www.onconova.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees23

Key Executives

NameTitlePayExercisedAge
Dr. Ramesh Kumar Ph.D.Co-Founder, Chief Exec. Officer, Pres & Director686.91kN/A61
Dr. E. Premkumar Reddy Ph.D.Founder, Lead Scientific Advisor & Director161kN/A73
Dr. Manoj Maniar Ph.D.Sr. VP of Product Devel.509.57kN/A54
Dr. Steven M. Fruchtman M.D.Chief Medical Officer & Sr. VP of R&D571.76kN/A66
Mr. Mark Patrick GuerinChief Financial OfficerN/AN/A48
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Corporate Governance

Onconova Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.